- Home
- ELTX vs SLQT Comparison
ELTX vs SLQT Comparison
Compare ELTX & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELTX | SLQT |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 72.4M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELTX | SLQT |
|---|---|---|
| Price | $1.90 | $0.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $13.67 | $2.13 |
| AVG Volume (30 Days) | 258.8K | ★ 1.2M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $1,618,499,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.02 |
| 52 Week Low | $1.44 | $0.30 |
| 52 Week High | $16.00 | $2.22 |
Technical Indicators
Market Signals| Indicator | ELTX | SLQT |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 30.33 |
| Support Level | $1.74 | N/A |
| Resistance Level | $1.97 | $0.78 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 79.63 | 4.84 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
About SLQT SelectQuote Inc.
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. Its insurance distribution business allows consumers to transparently and conveniently shop for senior health, life, and automobile and home insurance policies from a curated panel of the nation's insurance carriers. It operates in three reportable segments: Senior, Healthcare Services, and Life. Senior sells senior Medicare-related health insurance products. Healthcare Services includes SelectRx, Healthcare Select, and SPM. Healthcare Services provides products and services to its Medicare policyholders, which are focused on improving patient health outcomes. Life sells term life and final expense products.